UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current
Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2005
Metabasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-50785 |
|
33-0753322 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
incorporation) |
|
|
|
Identification No.) |
|
11119 North Torrey Pines Road |
|
|
|
La Jolla, California |
|
92037 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 587-2770
9390 Towne Centre Drive, Building 300
San Diego, California 92121
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 10, 2005, we announced financial results for the third quarter ended September 30, 2005 in the earnings release attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press release of Metabasis Therapeutics, Inc. dated November 10, 2005.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
METABASIS THERAPEUTICS, INC. |
||
|
|
|
|
|
|
|
By: |
/s/ John W. Beck |
|
|
|
|
John W. Beck |
|
|
|
|
|
|
|
Date: November 10, 2005 |
|
|
|
3
INDEX TO EXHIBITS
99.1 Press release of Metabasis Therapeutics, Inc. dated November 10, 2005.
4